Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ascendis Pharma (ASND – Research Report), Rubius Therapeutics (RUBY – Research Report) and Connect Biopharma Holdings (CNTB – Research Report).
Ascendis Pharma (ASND)
In a report issued on September 13, Joseph Schwartz from SVB Securities reiterated a Buy rating on Ascendis Pharma, with a price target of $168.00. The company’s shares closed last Thursday at $109.29.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $150.50, representing a 42.5% upside. In a report issued on August 29, Berenberg Bank also initiated coverage with a Buy rating on the stock with a $166.00 price target.
See today’s best-performing stocks on TipRanks >>
Rubius Therapeutics (RUBY)
In a report issued on September 13, Jonathan Chang from SVB Securities maintained a Hold rating on Rubius Therapeutics, with a price target of $1.00. The company’s shares closed last Thursday at $0.69, close to its 52-week low of $0.65.
According to TipRanks.com, Chang is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Rubius Therapeutics with a $1.25 average price target, implying a 68.9% upside from current levels. In a report issued on September 13, Guggenheim also downgraded the stock to Hold.
Connect Biopharma Holdings (CNTB)
In a report issued on September 14, Thomas Smith from SVB Securities reiterated a Buy rating on Connect Biopharma Holdings, with a price target of $9.00. The company’s shares closed last Thursday at $1.46, close to its 52-week low of $0.56.
According to TipRanks.com, Smith is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Connect Biopharma Holdings is a Moderate Buy with an average price target of $5.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ASND:
